EcoR1 Capital, a biotech-focused investment advisory firm, and RTW Investments, an investment firm focused on investments in the biopharma space, completed a $350m investment in Arvinas, a biopharmaceutical company specializing in protein degradation-based treatments, with participation from Adage Capital Partners, ArrowMark Partners, Avidity Partners, BB Biotech, Boxer Capital, Citadel Global Equities, Great Point Partners, Nextech Invest, RA Capital Management, and Surveyor Capital. The infusion of capital is earmarked for the advancement of Arvinas’ clinical and preclinical programs, which include promising drug candidates such as ARV-766 for prostate cancer and vepdegestrant (ARV-471), which targets breast cancer. These programs are part of Arvinas’ innovative approach to cancer treatment, utilizing their PROTAC Discovery Engine platform that focuses on protein degradation mechanisms.